Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

13.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
13.5K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

8.1K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.1K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

2.2K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
2.2K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune checkpoint therapy in pediatric and adolescent lymphomas.

Haematologica·2026
Same author

Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response.

Blood cancer journal·2026
Same author

Aging cells, young patients: senescence in Hodgkin lymphoma.

Blood advances·2026
Same author

How can we safely eliminate RT in pediatric HL?

Blood·2026
Same author

On the CHOPping block? Rethinking initial therapy for PMBCL.

Blood·2025
Same author

Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study.

Transplantation and cellular therapy·2025
Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026
Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026
Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026
Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026
Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026
Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026
See all related articles

Related Experiment Video

Updated: Nov 12, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K

AYA Considerations for Aggressive Lymphomas.

Gabriela Llaurador1,2, Lisa Giulino-Roth3

  • 1Division of Pediatric Hematology Oncology, Weill Cornell Medical College, 525 E 68th Street, Payson 695, New York, NY, 10065, USA.

Current Hematologic Malignancy Reports
|March 17, 2021
PubMed
Summary
This summary is machine-generated.

Outcomes for adolescents and young adults (AYAs) with lymphoma, particularly Hodgkin lymphoma (HL) and primary mediastinal B cell lymphoma (PMBCL), lag behind other age groups. New targeted therapies and AYA-focused clinical trials are crucial for improving survival and reducing toxicity.

Keywords:
AYAAdolescentHodgkin lymphomaLymphomaPrimary mediastinal B cell lymphomaYoung adult

More Related Videos

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

213
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.2K

Related Experiment Videos

Last Updated: Nov 12, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.6K
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

213
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.2K

Area of Science:

  • Hematology
  • Oncology
  • Adolescent and Young Adult Medicine

Background:

  • Lymphoma is a common cancer diagnosis in adolescents and young adults (AYAs, 15-39 years).
  • Improvements in AYA outcomes have lagged compared to pediatric and older adult populations.
  • Contributing factors include healthcare access disparities, low clinical trial enrollment, unique disease biology, and psychosocial challenges.

Purpose of the Study:

  • To review Hodgkin lymphoma (HL) and primary mediastinal B cell lymphoma (PMBCL) in AYAs.
  • To discuss AYA disease biology, current treatment strategies, and novel targeted therapies.
  • To highlight AYA-specific toxicities, psychosocial issues, and ongoing clinical trials.

Main Methods:

  • Review of current knowledge on AYA lymphoma subtypes.
  • Analysis of pediatric and adult treatment strategies.
  • Evaluation of novel targeted agents and AYA-focused clinical trials.

Main Results:

  • Dose-intense chemotherapy with or without radiation yields high cure rates but carries long-term toxicity risks.
  • Novel agents like brentuximab vedotin and PD-1/PD-L1 inhibitors show promise, especially in relapsed settings.
  • Ongoing AYA trials aim to optimize upfront therapy and reduce treatment-related toxicities.

Conclusions:

  • There is an urgent need for AYA-specific clinical trials to understand age-related outcomes and toxicities.
  • Developing comprehensive AYA care models is essential to address their unique needs.
  • Targeted therapies may reduce reliance on treatments with significant long-term toxicity.